Posted by Michael Wonder on 19 Sep 2016
Talimogene laherparepvec in melanoma: additional clinical benefit not proven
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment.
Talimogene laherparepvec (Imlygic) has been approved since December 2015 for adults with advanced melanoma. The German IQWiG examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patients.
However, since the manufacturer dossier contained no suitable data, no added benefit of talimogene laherparepvec could be derived from it.
